Company

BioNTech SE

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 1/2 TRIAL

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

ClinicalTrials.gov

First-in-human Phase 1/2 study registration with no posted results; safety and dose-escalation design in early development stage.

PreliminaryNCT06750185 Advanced Solid Tumor BNT317 DL4

Reported

Estimated enrollment248

Study phasePhase 1/Phase 2

Primary outcome (Part A)Occurrence of dose-limiting toxicities (DLT…

SEP 8, 2026 · PHASE 3 TRIAL

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

ClinicalTrials.gov

This is a clinical trial registry record describing a Phase 3 RCT that is currently recruiting with no results posted; the study design is rigorous but outcomes are not yet available.

PreliminaryPumitamig Nab-paclitaxel/Paclitaxel Breast Neoplasms

Reported

Planned sample size558

PhasePHASE 3

Primary endpoint 1Progression-Free Survival (PFS) as Assessed…

AUG 13, 2026 · PHASE 2/3 TRIAL

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

ClinicalTrials.gov

This is a recruiting Phase 2/3 trial registration with no reported results; primary outcomes remain unassessed and data are not yet available to evaluate efficacy or safety.

PreliminaryPumitamig NCT06712316 Pembrolizumab

Reported

Planned enrollment1580

Phase 2 primary endpoint (safety)Treatment-emergent adverse events (TEAE) in…

Phase 2 primary endpoint (efficac…Objective response rate (ORR) and best perc…